CD274 and hepatocellular carcinoma: Moreover, while ICIs have transformed cancer treatment of HCC and the therapeutic effect of ICI (programmed cell death (PD)-1/programmed death-ligand1 (PD-L)1 antibody), combined ICI therapies, tyrosine kinase inhibitor (TKI) and ICI + locoregional treatment, enhancing antitumor immune responses, only few patients benefit from these therapies [100].